MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

Table of Contents

1. Overview and Terminology Update
2. Disease Spectrum: From Steatosis to Cirrhosis
3. Pathophysiology: The Multiple-Hit Model
4. Epidemiology, Risk Factors, and Genetic Variants
5. Diagnosis and Non-Invasive Assessment
6. Treatment: Lifestyle Interventions
7. Pharmacological Treatment
8. Fibrosis Progression, HCC, and Surveillance
9. Key Research Papers
10. PubMed Topic Searches
11. Connections
12. Featured Videos

Overview and Terminology Update

MASLD (metabolic dysfunction-associated steatotic liver disease), formerly known as NAFLD (non-alcoholic fatty liver disease), is the most common chronic liver disease in the world. In 2023, a landmark multi-society Delphi consensus — coordinated by AASLD, EASL, APASL, and other major hepatology organizations — formally adopted new nomenclature to better reflect the disease's metabolic underpinnings and to reduce the stigma of the prior "non-alcoholic" framing (Rinella et al., 2023, PMID 37363821).

Both terms will appear in clinical and scientific literature for years to come. Throughout this page, MASLD (formerly NAFLD) refers to the same condition. The name change carries diagnostic weight: MASLD now requires hepatic steatosis (fat in >5% of hepatocytes on biopsy or imaging equivalent) plus at least one of five cardiometabolic risk factors:

• BMI >25 kg/m² (or >23 kg/m² in Asian populations)
• Waist circumference >102 cm (men) or >88 cm (women)
• Fasting triglycerides ≥150 mg/dL (or on lipid-lowering therapy)
• HDL-C <40 mg/dL (men) or <50 mg/dL (women) (or on HDL-raising therapy)
• Prediabetes, type 2 diabetes mellitus (T2DM), or hypertension (≥130/85 mmHg)

The revised nomenclature also introduced MetALD — a new category for patients who meet MASLD criteria but also consume moderate amounts of alcohol (140–350 g/week in women; 210–420 g/week in men). MetALD sits between MASLD and alcohol-related liver disease (ALD), acknowledging that metabolic dysfunction and alcohol act synergistically to drive liver injury.

The scale of this disease is staggering. Globally, MASLD affects approximately 38% of adults — over 1.5 billion people worldwide. In the United States, more than 100 million people are estimated to have MASLD. Among people with obesity, prevalence exceeds 50%; in those with type 2 diabetes, 60–70% have MASLD. The disease spans the full spectrum from benign fat accumulation to cirrhosis and hepatocellular carcinoma (HCC).

Back to Table of Contents

Disease Spectrum: From Steatosis to Cirrhosis

MASLD encompasses a progressive spectrum of histological stages with markedly different outcomes. Understanding this spectrum is essential for both patient counseling and clinical decision-making.

MASL — Metabolic Dysfunction-Associated Steatotic Liver (Simple Steatosis)

At the benign end of the spectrum, MASL (simple steatosis without inflammation) describes fat infiltrating more than 5% of hepatocytes without evidence of hepatocellular injury or fibrosis. Most patients have no symptoms. Annual risk of progression to MASH is approximately 4%; the 10-year risk of cirrhosis is low (<5%). The majority of patients with simple steatosis do not progress — particularly if underlying metabolic risk factors are controlled.

MASH — Metabolic Dysfunction-Associated Steatohepatitis

MASH (formerly NASH) is the inflammatory, progressive form of MASLD. Diagnosis requires liver biopsy showing steatosis, lobular inflammation, and hepatocyte ballooning — a characteristic swelling of hepatocytes indicating cellular stress and injury. MASH is formally defined by the NAFLD Activity Score (NAS) (Kleiner et al., 2005, PMID 15915461):

• NAS ≥5 with at least 1 point each for steatosis, lobular inflammation, and ballooning = diagnostic of MASH
• NAS ≤3 = not MASH
• NAS 4 = borderline; clinical judgment applies
• Fibrosis stage (F0–F4) is scored separately from NAS — fibrosis reflects cumulative injury, not current activity

MASH affects approximately 20–30% of those with MASLD. Annual risk of progression to cirrhosis: 3–15% depending on baseline fibrosis stage. The presence of advanced fibrosis (F3) carries particularly high mortality risk.

Fibrosis Staging (F0–F4)

Liver fibrosis — scarring from chronic hepatocyte injury and stellate cell activation — is staged independently from steatohepatitis activity:

• F0 — no fibrosis
• F1 — perisinusoidal or periportal fibrosis only
• F2 — perisinusoidal + periportal fibrosis
• F3 — bridging fibrosis (connections between portal tracts and central veins)
• F4 — cirrhosis (complete architectural distortion, nodule formation)

Fibrosis stage is the single strongest predictor of liver-related mortality and all-cause mortality in MASLD — more predictive than NAS or the presence of MASH itself. Every increment in fibrosis stage roughly doubles liver-related mortality risk.

Cirrhosis (F4)

Cirrhosis is architecturally irreversible scarring. Once cirrhosis develops, complications of portal hypertension can emerge: esophageal and gastric varices (at risk for catastrophic hemorrhage), ascites (abdominal fluid), spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy (confusion from ammonia accumulation). Annual HCC risk in MASLD cirrhosis is 1–2% per year.

Hepatocellular Carcinoma (HCC)

MASLD is now the leading or co-leading etiology of HCC in the United States, surpassing hepatitis C in incidence. A critical distinction from HCV-related HCC: 10–15% (some estimates up to 50%) of MASLD-related HCC occurs in patients without cirrhosis. This non-cirrhotic HCC development complicates standard surveillance protocols designed around cirrhosis, and is an area of active investigation.

Back to Table of Contents

Pathophysiology: The Multiple-Hit Model

The pathophysiology of MASLD is now understood through a "multiple-hit" model — insulin resistance provides the vulnerable metabolic foundation (first hit), while additional stressors drive inflammation and fibrosis progression (second and third hits).

First Hit: Insulin Resistance and Hepatic Fat Accumulation

Insulin resistance is the central metabolic defect in MASLD. At the liver level, insulin resistance drives:

• Increased de novo lipogenesis (DNL) — the liver synthesizes fatty acids from excess carbohydrates (particularly fructose); DNL contributes up to 26% of hepatic triglyceride in MASLD vs. ~5% in healthy controls
• Increased free fatty acid (FFA) flux from visceral adipose tissue — insulin-resistant adipocytes fail to suppress lipolysis, flooding the portal circulation with FFAs
• Impaired mitochondrial beta-oxidation — overwhelmed by excess fatty acid load; surplus FFAs accumulate as hepatic triglycerides

Second Hit: Oxidative Stress

Excess FFAs overwhelm mitochondrial beta-oxidation capacity. The overflow is shunted to microsomal oxidation (CYP2E1) and peroxisomal oxidation, generating reactive oxygen species (ROS). ROS cause:

• Lipid peroxidation of hepatocyte membranes
• Activation of inflammatory signaling cascades (NF-κB, JNK pathways)
• Mitochondrial DNA damage and dysfunction (self-perpetuating cycle)
• Upregulation of CYP2E1, which generates additional oxidant stress

Dietary Fructose: A Key Accelerant

High-fructose corn syrup and added sugars are strongly implicated in the epidemic rise of MASLD. Unlike glucose, fructose is metabolized almost exclusively in the liver via hepatic fructokinase (KHK), bypassing the regulatory steps of glycolysis. This creates:

• Rapid ATP depletion and uric acid generation (via AMP deaminase)
• Unregulated hepatic lipogenesis (fructose → acetyl-CoA → fatty acids via SREBP-1c)
• Uric acid-mediated inhibition of endothelial nitric oxide synthase → increased blood pressure and insulin resistance

Gut-Liver Axis: Dysbiosis and LPS Translocation

Patients with MASLD consistently show gut microbiome dysbiosis — reduced diversity, enrichment of Firmicutes, depletion of Bacteroidetes. This dysbiosis increases intestinal permeability ("leaky gut"), allowing bacterial lipopolysaccharide (LPS) and other microbial products to translocate into the portal circulation. LPS activates hepatic Kupffer cells (liver macrophages) via TLR4, triggering:

• TNF-α and IL-6 secretion → hepatocyte apoptosis and inflammation
• TGF-β secretion → hepatic stellate cell (HSC) activation
• NLRP3 inflammasome activation → IL-1β → liver injury amplification

Stellate Cell Activation and Fibrogenesis

Hepatic stellate cells (HSCs) are the primary fibrogenic cells in the liver. In response to chronic injury signals (ROS, TGF-β, PDGF), HSCs transdifferentiate from quiescent vitamin A-storing cells into activated myofibroblasts that deposit collagen (primarily type I and III). Progressive collagen deposition replaces functional hepatocyte mass with scar tissue — the histological basis of fibrosis. In compensated cirrhosis, some fibrosis can regress with sustained MASH resolution; F4 cirrhosis with established architectural distortion is generally irreversible.

Key Genetic Risk Factors

• PNPLA3 I148M (rs738409) — the most influential common genetic variant; the Met148 allele impairs triglyceride hydrolysis in hepatocytes and HSCs; carriers have 3.2× higher MASH risk and 5× higher HCC risk; enriched in Hispanic populations (allele frequency ~49% vs ~23% in Europeans vs ~17% in African Americans) (Romeo et al., 2008, PMID 18820647)
• TM6SF2 E167K (rs58542926) — reduces hepatic VLDL secretion, promoting lipid retention; associated with higher MASH and fibrosis risk, but paradoxically lower cardiovascular risk
• MBOAT7 rs641738 — reduces phosphatidylinositol remodeling; associated with MASLD and fibrosis, especially in European populations
• HSD17B13 rs72613567 — a splice variant that reduces MASLD and HCC risk; carriers have slower fibrosis progression — this loss-of-function variant is considered protective
• GCKR rs1260326 — increases hepatic glucokinase activity, promoting DNL; common risk variant for hepatic steatosis

Back to Table of Contents

Epidemiology, Risk Factors, and Genetic Variants

MASLD has reached epidemic proportions globally, with prevalence rising in parallel with rates of obesity, type 2 diabetes, and metabolic syndrome (Younossi et al., 2016, PMID 26707365).

Global and US Prevalence

• Global prevalence: ~38% of adults (up from ~25% in the early 2000s)
• United States: 100 million+ affected; 40–50%+ prevalence in adults with obesity
• MASH: approximately 15–20% of those with MASLD, meaning 15–20 million Americans have the progressive form
• Advanced fibrosis (F3–F4): approximately 3–5% of all adults with MASLD; ~5 million Americans

Ethnic Variation

MASLD prevalence varies substantially by ethnicity, partly driven by genetic factors:

• Hispanic Americans: ~45% — highest prevalence; driven substantially by enrichment of PNPLA3 I148M allele, particularly in Mexican-American and Puerto Rican populations
• Non-Hispanic White Americans: ~33%
• Asian Americans: ~15–25% — lower absolute prevalence but MASLD and metabolic risk occur at lower BMI thresholds; BMI >23 kg/m² is used as the obesity threshold in Asian populations
• African Americans: ~24% — paradoxically lower prevalence despite higher rates of obesity and T2DM; partly explained by lower PNPLA3 I148M allele frequency and possibly protective ADIPOQ (adiponectin gene) variants

Pediatric MASLD

Pediatric MASLD (children 2–18 years) affects an estimated 10–17% of children overall and up to 38% in obese children. The pediatric form is rising with childhood obesity rates and is increasingly recognized as a major public health concern. PNPLA3 I148M confers the same risk in children. Pediatric MASLD histology shows a "zone 1" periportal predominance (unlike the zone 3 perivenous pattern in adults), and progression can be rapid.

High-Risk Comorbidities

• Type 2 diabetes: 60–70% of T2DM patients have MASLD; T2DM doubles the risk of progression to cirrhosis
• Obesity (BMI >30): ~50% MASLD prevalence; BMI >40: ~80–90%
• Polycystic ovary syndrome (PCOS): 30–70% of women with PCOS have MASLD, independent of BMI — driven by hyperinsulinemia and androgen excess
• Hypothyroidism: impairs hepatic lipid clearance and reduces fatty acid oxidation; independently associated with MASLD and fibrosis severity
• Obstructive sleep apnea (OSA): intermittent hypoxia independently promotes hepatic oxidative stress and fibrosis, beyond the effect of shared obesity risk
• Chronic kidney disease (CKD): MASLD and CKD share bidirectional causal mechanisms via insulin resistance, systemic inflammation, and dyslipidemia; each accelerates the other

Cardiovascular Risk

The most important clinical point: cardiovascular disease is the leading cause of death in MASLD patients — not liver failure. MASLD is an independent cardiovascular risk factor beyond traditional Framingham risk factors. Patients with MASLD have a 1.6–2.2-fold elevated risk of major adverse cardiovascular events (MACE). Aggressive management of blood pressure, LDL-C, and glucose is therefore essential in all MASLD patients, regardless of liver disease stage.

Back to Table of Contents

Diagnosis and Non-Invasive Assessment

The diagnostic approach to MASLD has evolved substantially with validated non-invasive tools that can identify most patients who need specialist referral — reserving liver biopsy for cases where it will change management.

Initial Laboratory Evaluation

• Liver enzymes (AST, ALT): often mildly elevated in MASH (typically ALT > AST; the reverse of alcohol-related liver disease where AST:ALT >2); however, normal enzymes do not exclude MASLD or even advanced fibrosis — approximately 25% of patients with advanced fibrosis have normal ALT
• Complete metabolic panel: assess albumin, bilirubin, and prothrombin time for signs of hepatic synthetic dysfunction in advanced disease
• Fasting lipids, glucose, HbA1c: document cardiometabolic risk factors needed for MASLD classification and comorbidity management

FIB-4 Index — First-Line Fibrosis Triage

The FIB-4 index is the most widely validated, low-cost non-invasive fibrosis assessment tool and is recommended as first-line triage by AASLD, AGA, ACG, and EASL (Angulo et al., 2007, PMID 17393509):

FIB-4 = (Age × AST) / (Platelet count [10&sup9;/L] × √ALT)

• FIB-4 <1.30 — low risk of advanced fibrosis (F0–F2); negative predictive value ~95%; reassure and monitor in primary care
• FIB-4 1.30–2.67 — indeterminate; refer for second-line testing (FibroScan, ELF, or hepatology consultation)
• FIB-4 >2.67 — high risk of advanced fibrosis (F3–F4); positive predictive value ~70%; refer to hepatology; liver biopsy may be indicated

Age adjustment: Use a higher cutoff of >3.25 for "high risk" in patients over 65 years (standard 2.67 overestimates fibrosis in the elderly); lower threshold of >2.0 may be more appropriate in patients under 35 where standard thresholds underestimate risk.

Vibration-Controlled Transient Elastography (VCTE/FibroScan)

FibroScan measures liver stiffness (kPa) as a surrogate for fibrosis, plus controlled attenuation parameter (CAP dB/m) for steatosis quantification. Key thresholds:

• Liver stiffness <8 kPa — low likelihood of significant fibrosis (F≥2)
• Liver stiffness >12 kPa — suggests advanced fibrosis (F3–F4)
• Liver stiffness >17 kPa — strongly suggests cirrhosis (F4)
• CAP <248 dB/m = no steatosis; 248–267 = mild (S1); 268–279 = moderate (S2); ≥280 = severe (S3)

Important caveats: FibroScan results are falsely elevated by recent food intake (should be fasting ≥2 hours), active hepatic inflammation (elevated transaminases >5× ULN), hepatic congestion (heart failure), and operator experience. BMI >35 may require an XL probe.

MRI-PDFF (Proton Density Fat Fraction)

MRI-PDFF is the most accurate non-invasive method for quantifying hepatic steatosis, with near-biopsy-level accuracy. It measures fat as a percentage of liver proton density. MR elastography (MRE) simultaneously quantifies liver stiffness with accuracy superior to FibroScan for staging fibrosis (especially F2–F3 discrimination). MRI-PDFF is the standard endpoint in most modern MASH clinical trials but remains expensive and limited to research and specialist centers.

Enhanced Liver Fibrosis (ELF) Panel

The ELF test (FDA-cleared in the US) combines three serum markers of fibrogenesis: hyaluronic acid, N-terminal procollagen III peptide (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1). ELF <7.7 = low fibrosis; ≥9.8 = advanced fibrosis. Useful as a second-line test when FIB-4 is indeterminate.

Liver Biopsy (Gold Standard)

Liver biopsy remains the gold standard for definitive MASH diagnosis and fibrosis staging. Histological scoring uses the NAS (NAFLD Activity Score) as described above. Biopsy is indicated when:

• Non-invasive tests are discordant or indeterminate and the distinction between MASH and simple steatosis would change management
• Competing diagnoses cannot be excluded non-invasively (e.g., autoimmune hepatitis)
• Enrollment in a clinical trial requires biopsy confirmation
• Fibrosis stage is critical to a management decision (e.g., resmetirom eligibility requires F2–F3)

Limitations: 10–20% sampling error (the biopsy represents ~1/50,000 of total liver volume); procedural risk (serious complications in 0.1–0.5%); cost; requires experienced hepatopathologist for accurate NAS scoring.

Back to Table of Contents

Treatment: Lifestyle Interventions

Lifestyle modification remains the cornerstone of MASLD treatment and the only intervention proven to reverse fibrosis at all stages (Vilar-Gomez et al., 2015, PMID 25865049). The dose-response relationship between weight loss and histological improvement is well established:

Weight Loss Targets and Histological Benefits

• 3–5% weight loss: reduces hepatic steatosis in most patients
• 7–10% weight loss: achieves MASH resolution in the majority of patients with documented MASH
• ≥10% sustained weight loss: associated with fibrosis regression ≥1 stage in approximately 45% of patients; complete MASH resolution in up to 90% when maintained long-term

A caloric deficit of 500–1,000 kcal/day below estimated total daily energy expenditure is the standard recommendation. The specific macronutrient composition matters less than overall caloric reduction and adherence.

Mediterranean Diet — Best Evidence

The Mediterranean diet has the strongest evidence base among dietary patterns for MASLD. It reduces hepatic steatosis independent of caloric restriction — likely via its anti-inflammatory composition: extra-virgin olive oil (oleocanthal and oleic acid reduce hepatic inflammation), fish (omega-3 fatty acids reduce DNL), legumes, whole grains, vegetables, and nuts (fiber supports gut microbiome diversity). Polyphenols from olive oil, red wine, and vegetables activate SIRT1, AMPK, and PPARα — all of which promote hepatic fatty acid oxidation and reduce lipogenic gene expression.

Low-Carbohydrate and Low-Fructose Approaches

• Eliminate sugar-sweetened beverages and high-fructose corn syrup — the single most impactful specific dietary change for MASLD; fructose directly drives hepatic DNL, bypassing insulin regulation
• Low-carbohydrate diets (<50g/day) — produce rapid reductions in hepatic fat (measurable by MRI within 2 weeks); particularly effective in insulin-resistant individuals; long-term adherence and fibrosis data are limited
• Ketogenic diet — rapid and substantial hepatic fat reduction; mechanistically sound; concerns about sustainability, potential for muscle loss, and lipid effects in some patients

Exercise

Physical activity independently reduces hepatic steatosis even without weight loss — a particularly important point for patients who struggle with dietary adherence:

• Aerobic exercise (150–300 min/week at moderate intensity): reduces hepatic fat by 3–10% absolute reduction on MRI-PDFF; improves mitochondrial function, insulin sensitivity, and adipokine profiles
• Resistance training: additive benefit to aerobic exercise; independently reduces liver fat; increases muscle mass (a major site of glucose disposal, improving whole-body insulin sensitivity)
• High-intensity interval training (HIIT): emerging evidence for superior efficiency in reducing hepatic fat per unit time compared to moderate-intensity continuous exercise

Alcohol Abstinence

Complete alcohol abstinence is recommended for patients with any degree of fibrosis (F≥1). Even moderate alcohol consumption (<14 drinks/week) accelerates fibrosis progression in patients with established MASH. The MetALD category in the 2023 nomenclature acknowledges that moderate alcohol in the context of metabolic risk creates additive liver injury — but the safe alcohol threshold in MASLD has not been established.

Coffee

Regular coffee consumption (2–3 cups/day) is consistently associated with lower hepatic fibrosis risk and reduced all-cause mortality in patients with MASLD across multiple large observational cohorts. The mechanisms likely include: polyphenol-mediated PPARα activation, antioxidant effects of chlorogenic acid, reduction of hepatic stellate cell activation by kahweol and cafestol, and anti-inflammatory effects via adenosine receptor antagonism. This is observational data but remarkably robust across ethnicities and coffee preparation methods. Instant coffee confers the same benefit as filtered coffee in most studies.

Bariatric and Metabolic Surgery

For patients with BMI ≥35 and MASLD/MASH who cannot achieve adequate weight loss through lifestyle modification alone, bariatric surgery is the most consistent intervention for sustained MASLD improvement. Meta-analyses show MASH resolution in 60–85% and fibrosis improvement in 30–50% after surgery. Sleeve gastrectomy and Roux-en-Y gastric bypass both show benefit. Bariatric surgery is contraindicated in decompensated cirrhosis (Child-Pugh C); risk-benefit assessment is required in compensated cirrhosis (Child-Pugh A–B).

Back to Table of Contents

Pharmacological Treatment

For decades, no drug was approved specifically for MASH. That changed in 2024 with the first FDA approval — and the pipeline now includes several promising agents across different mechanistic classes.

Resmetirom (Rezdiffra) — FDA Approved March 14, 2024

Resmetirom is the first and currently only FDA-approved drug for MASH with liver fibrosis (F2–F3). It is a thyroid hormone receptor beta (THRβ) selective agonist designed to act primarily in the liver:

• Mechanism: THRβ is the predominant thyroid hormone receptor in the liver. Selective activation increases hepatic fatty acid oxidation, reduces de novo lipogenesis (via suppression of SREBP-1c and FASN), increases LDL receptor expression, and reduces hepatic triglyceride content. Selectivity for THRβ (vs THRα, which predominates in heart and bone) avoids the cardiac and bone side effects of supraphysiologic thyroid hormone
• MAESTRO-NASH trial (Harrison et al., 2024, PMID 38324483): 966 patients with MASH (NAS ≥4) and fibrosis F2–F3 randomized to resmetirom 80 mg/day, 100 mg/day, or placebo for 52 weeks. Primary endpoints met:
  • MASH resolution without worsening fibrosis: 26% (80mg) vs 14% (placebo), p<0.001
  • Fibrosis improvement ≥1 stage without worsening NAS: 24% (80mg) vs 14% (placebo), p<0.001
• Dosing: 80 mg/day for patients <100 kg; 100 mg/day for patients ≥100 kg or homozygous for PNPLA3 I148M
• Common adverse effects: nausea (19% vs 10% placebo), diarrhea (17% vs 9%); predominantly mild-to-moderate and occurred early in treatment
• Drug interactions: inhibits CYP2C8 and is a CYP3A4 substrate; significant interactions with statins (resmetirom increases statin AUC — dose adjustments required for rosuvastatin and simvastatin)
• Contraindications: decompensated cirrhosis (Child-Pugh B or C); concomitant use of strong CYP2C8 inhibitors; thyroid monitoring required (can unmask subclinical hypothyroidism)
• Approved indication: MASH with moderate-to-advanced liver fibrosis (F2–F3), consistent with an adequate diet and exercise program

GLP-1 and GLP-1/GIP Receptor Agonists (Off-Label for MASH)

GLP-1 receptor agonists, developed for T2DM and obesity, have emerged as highly efficacious agents for MASH, though none carry a specific MASH FDA approval as of this writing.

• Semaglutide (Ozempic/Wegovy): NEJM 2021 (Newsome et al., PMID 33185364) — 59% MASH resolution vs 17% placebo at 72 weeks; fibrosis improvement was numerically higher but did not reach statistical significance (43% vs 33%, P=0.48), likely due to underpowering and short duration. Phase 3 ESSENCE trial (semaglutide 2.4 mg weekly, the weight-management dose) in F2–F3 MASH reported in 2024: significantly higher MASH resolution AND fibrosis improvement vs placebo — regulatory submission anticipated
• Tirzepatide (Mounjaro/Zepbound): GIP/GLP-1 dual agonist; SYNERGY-NASH trial in 2024: 62% MASH resolution vs 11% placebo, and 51% fibrosis improvement ≥1 stage vs 30% placebo — superior numerical efficacy to semaglutide, possibly attributable to GIP receptor-mediated effects on hepatic stellate cells and adipose tissue
• Common caution: avoid in personal or family history of medullary thyroid carcinoma or MEN2 syndrome; not recommended with active pancreatitis
• Insurance coverage: GLP-1 agonists for MASH in patients who lack T2DM or obesity approval criteria is highly variable; the on-label T2DM or obesity indication often enables access

SGLT2 Inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce hepatic steatosis and modestly improve liver enzymes and fibrosis markers in MASLD, particularly when T2DM coexists. They are increasingly used in MASLD patients with T2DM on the basis of their favorable metabolic and cardiovascular profiles, even without MASLD-specific approval. Phase 3 MASLD-specific trials are ongoing.

Vitamin E (Alpha-Tocopherol) 800 IU/day

The PIVENS trial (Sanyal et al., 2010, PMID 20427778) showed that vitamin E 800 IU/day improved NAS and achieved more MASH resolution than placebo in non-diabetic adults with documented MASH — a significant effect before any approved pharmacotherapy existed. Practical considerations limit enthusiasm:

• Benefit shown only in non-diabetic adults without cirrhosis; not validated in T2DM or advanced fibrosis
• Observational data suggest increased all-cause mortality and hemorrhagic stroke at doses ≥400 IU/day (SELECT trial showed increased prostate cancer risk)
• No fibrosis benefit was demonstrated in PIVENS
• Current use: some hepatologists still prescribe for non-diabetic MASH patients unwilling or unable to take other agents; should be discussed with full risk-benefit disclosure

Pioglitazone

Pioglitazone is a PPARy agonist (thiazolidinedione insulin sensitizer) that improves MASH histology including fibrosis in patients with and without T2DM. PIVENS showed a signal for fibrosis improvement that vitamin E did not. Practical limitations: weight gain (3–5 kg average), fluid retention, bone density loss in women, and a possible association with bladder cancer (long-term use). Appropriate for select MASH patients with well-documented insulin resistance, particularly those who are diabetic and have failed other options.

Other Emerging Pipeline Agents

• Lanifibranor (PPAR pan-agonist): NATIVE trial showed significant MASH resolution and fibrosis improvement; under regulatory review in Europe
• Efruxifermin (FGF21 analog): Phase 3 SYNCHRONY-NASH trial ongoing; Phase 2 showed significant fibrosis improvement
• Obeticholic acid (FXR agonist, REGENERATE trial): showed fibrosis improvement but development complicated by dose-dependent pruritus and LDL elevation; FDA approval application under review for fibrosis endpoint
• Aldafermin (FGF19 analog): reduces hepatic lipogenesis via SHP1/SREBP-1c suppression; Phase 2 data promising

Back to Table of Contents

Fibrosis Progression, HCC, and Surveillance

Natural History and Fibrosis Progression Rates

Fibrosis progression in MASLD is highly variable and not inevitable. Key data points:

• The average rate of fibrosis progression in MASH is approximately 1 stage every 7 years, but with enormous individual variability
• Approximately 30–40% of patients with MASH show no fibrosis progression over 5 years; 20% progress by ≥2 stages
• Risk factors for faster fibrosis progression: T2DM (doubles risk), ALT >2× ULN, lobular inflammation, hepatocyte ballooning, PNPLA3 I148M homozygosity, age >50, and hypertension
• "Burned-out NASH" is an important concept: in some patients with advanced cirrhosis, the original MASH has spontaneously resolved (inflammation burned out), leaving only fibrosis/cirrhosis on biopsy — making the original diagnosis difficult to establish retrospectively
• Spontaneous fibrosis regression can occur with sustained MASH resolution, particularly with weight loss, pharmacotherapy, or bariatric surgery — most consistently demonstrated at F1–F3; F4 reversal is rare

Cirrhosis Complications and Management

Once cirrhosis (F4) develops, management shifts toward monitoring and treating portal hypertension complications:

• Variceal surveillance: upper endoscopy at diagnosis of cirrhosis; every 1–3 years if no varices; non-selective beta-blockers (propranolol, carvedilol) for primary prophylaxis of large varices or high-risk features
• Ascites: dietary sodium restriction (<2g/day) + diuretics (spironolactone ± furosemide); large-volume paracentesis for refractory ascites; TIPS (transjugular intrahepatic portosystemic shunt) for refractory cases
• Hepatic encephalopathy (HE): lactulose (titrate to 2–3 soft bowel movements/day); rifaximin 550 mg twice daily for secondary prophylaxis after first HE episode
• SBP prophylaxis: norfloxacin or trimethoprim-sulfamethoxazole in patients with prior SBP or low-protein ascites
• Liver transplant evaluation: refer when MELD ≥15 or when hepatic decompensation occurs (jaundice, ascites, HE, variceal bleeding)

Hepatocellular Carcinoma — Key Features in MASLD

MASLD-related HCC has several features that distinguish it from HCV-related or alcohol-related HCC:

• MASLD is now the leading or co-leading etiology of HCC in the United States and much of Europe
• 10–15% of MASLD-HCC occurs in non-cirrhotic patients — a major clinical challenge because standard surveillance protocols are triggered by cirrhosis diagnosis
• Risk factors for non-cirrhotic MASLD-HCC: PNPLA3 I148M homozygosity, T2DM, male sex, age >60, advanced fibrosis (F3), and obesity
• HCC typically presents at a more advanced stage in MASLD compared to HCV, partly because non-cirrhotic patients are not enrolled in surveillance
• AFP has lower sensitivity in MASLD-HCC than in HCV-HCC; ultrasound alone may miss small lesions in obese patients

HCC Surveillance Protocols

• Cirrhotic MASLD: biannual liver ultrasound ± AFP per AASLD guidelines; consider MRI or CT surveillance in patients with BMI >35 where ultrasound is limited
• Non-cirrhotic MASLD (F3 + T2DM + PNPLA3 I148M): individualized surveillance decision; no consensus guideline yet; some experts recommend biannual surveillance in patients with multiple risk factors
• Multiphasic CT or MRI with contrast is required to characterize liver lesions ≥1 cm detected on surveillance (LI-RADS criteria); biopsy if imaging indeterminate

Liver Transplantation

MASLD/MASH cirrhosis is now the second most common indication for liver transplantation in the United States (after alcohol-related liver disease, which recently surpassed MASLD following COVID-19 era alcohol use surge). MASLD is projected to become the leading transplant indication within the decade.

• Pre-transplant optimization: achieve best possible metabolic control; cardiovascular evaluation is particularly important given the high cardiovascular comorbidity burden
• Post-transplant MASLD recurrence: occurs in 30–70% of recipients within 5 years; recurrence is driven by persistence of metabolic syndrome (obesity, T2DM, dyslipidemia) which is often exacerbated by immunosuppressive medications (tacrolimus, corticosteroids)
• MASLD recurrence rarely progresses to graft failure within the first decade; long-term outcomes generally good
• Metabolic syndrome management and lifestyle support are essential in post-transplant care to prevent MASLD recurrence and cardiovascular events (the leading cause of late post-transplant mortality)

Back to Table of Contents

Key Research Papers

1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PMID: 37363821
2. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. PMID: 38324483
3. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364
4. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). N Engl J Med. 2010;362(18):1675-1685. PMID: 20427778
5. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321. PMID: 15915461
6. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. PMID: 26707365
7. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465. PMID: 18820647
8. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378. PMID: 25865049
9. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-854. PMID: 17393509
10. Loomba R, Sanyal AJ. The global NAFLD epidemic. Gastroenterology. 2021;161(3):912-924. PMID: 34364554
11. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. PMID: 28714183
12. Romero-Gómez M, Zelber-Sagi S, Trenell M, et al. Steatotic liver disease: A multisystem disease. J Hepatol. 2024;80(2):310-323. PMID: 37726084

Back to Table of Contents

PubMed Topic Searches

Curated PubMed topic searches for peer-reviewed literature on MASLD. Each link opens a live PubMed query so you always see the most current studies.

1. PubMed: MASLD MASH treatment
2. PubMed: Resmetirom MASH fibrosis
3. PubMed: MASLD epidemiology prevalence
4. PubMed: PNPLA3 MASLD genetic risk
5. PubMed: FIB-4 MASLD noninvasive assessment
6. PubMed: Mediterranean diet MASLD

Back to Table of Contents

Connections

• Fatty Liver Disease (NAFLD/MASLD overview)
• Liver Cirrhosis
• Pancreatitis
• Esophageal Varices
• Autoimmune Hepatitis
• Gallbladder Disease
• Gallstones
• SIBO
• Irritable Bowel Syndrome
• Type 2 Diabetes
• Metabolic Syndrome
• Insulin Resistance
• Vitamin E
• Choline
• Milk Thistle (silymarin)
• Olive Oil (Mediterranean diet)
• Coffee
• Zinc

Back to Table of Contents

×

Featured Videos